The FDA is issuing two draft guidances, which, when finalized, will provide new and updated information for companies designed to increase the availability of high-quality safety information in drugs used during pregnancy or lactation.
Statement from Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D., and Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on policies designed to capture more data to better understand effects of prescription drugs in pregnant and nursing women
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
- Armstrong Medical Limited Recalls AMSORB PLUS PREFILLED G-CAN 1.0L Due to Reduced Gas Flow to Patients During Anesthesia
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals